Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Bionano Genomics stock

BNGO
US09075F1075
A2JRLZ

Price

0.25
Today +/-
-0.01
Today %
-3.90 %
P

Bionano Genomics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Bionano Genomics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bionano Genomics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bionano Genomics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bionano Genomics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bionano Genomics Stock Price History

DateBionano Genomics Price
11/15/20240.25 undefined
11/14/20240.26 undefined
11/13/20240.27 undefined
11/12/20240.26 undefined
11/11/20240.28 undefined
11/8/20240.28 undefined
11/7/20240.29 undefined
11/6/20240.30 undefined
11/5/20240.30 undefined
11/4/20240.28 undefined
11/1/20240.28 undefined
10/31/20240.29 undefined
10/30/20240.34 undefined
10/29/20240.31 undefined
10/28/20240.31 undefined
10/25/20240.31 undefined
10/24/20240.30 undefined
10/23/20240.29 undefined
10/22/20240.31 undefined
10/21/20240.32 undefined
10/18/20240.33 undefined

Bionano Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bionano Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bionano Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bionano Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bionano Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bionano Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bionano Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bionano Genomics’s growth potential.

Bionano Genomics Revenue, EBIT and net profit per share

DateBionano Genomics RevenueBionano Genomics EBITBionano Genomics Net Income
2029e192.91 M undefined0 undefined53.51 M undefined
2028e141.51 M undefined-4.07 M undefined16.67 M undefined
2027e103.66 M undefined-29.32 M undefined-11.4 M undefined
2026e54.99 M undefined-28.62 M undefined-26.75 M undefined
2025e43.79 M undefined-40.62 M undefined-43.27 M undefined
2024e36.09 M undefined-74.15 M undefined-102.34 M undefined
202336.12 M undefined-137.97 M undefined-232.49 M undefined
202227.8 M undefined-129.9 M undefined-132.6 M undefined
202117.98 M undefined-75.6 M undefined-72.44 M undefined
20208.5 M undefined-37.05 M undefined-41.11 M undefined
201910.13 M undefined-25.88 M undefined-29.82 M undefined
201812 M undefined-20.42 M undefined-18.5 M undefined
20179.51 M undefined-22.62 M undefined-23.37 M undefined
20166.79 M undefined-21.17 M undefined-18.85 M undefined

Bionano Genomics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
6912108172736364354103141192
-50.0033.33-16.67-20.00112.5058.8233.33-19.4425.5890.7436.8936.17
50.0033.3325.0030.0025.0017.6518.5225.0025.0020.9316.678.746.384.69
33332359000000
-18-23-18-29-41-72-132-232-102-43-26-111653
-27.78-21.7461.1141.3875.6183.3375.76-56.03-57.84-39.53-57.69-245.45231.25
0.950.951.011.510.4327.6828.9234.15000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Bionano Genomics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bionano Genomics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
5.2116.517.338.4250.6113.266.77
1.83.44.56.32.84.979.32
00000400500342
1.81.71.13.43.312.429.822.89
1.81.10.91.22.346.840.79
10.67.22328.246.8272.3157.3140.12
4.131.81.94.920.92932.48
00000000
00000000
00001.526.841.133.97
00007.256.277.30
00000.10.72.87.83
4.131.81.913.7104.6150.274.29
14.710.224.830.160.5376.9307.5214.4
               
25.443000000.01
3.6482.9106.2178.7553.7599.2677.34
-30.9-54.3-72.8-102.6-143.7-216.1-348.7-581.21
00000-500-1,10023
00000000
-1.9-7.310.13.635337.1249.496.16
0.82.31.42.72.99.712.510.38
2.93.52.93510.5129.14
5.14.10.30.611.411.180.24
00000000
0.66.7020.100.30.30.27
9.416.64.626.48.921.935.9100.03
609016.33.63.63.59
00000000
1.20.71.10.20.114.518.614.63
7.20.710.10.216.418.122.218.22
16.617.314.726.625.34058.1118.25
14.71024.830.260.3377.1307.5214.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bionano Genomics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bionano Genomics's financial health and stability.

Assets

Bionano Genomics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bionano Genomics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bionano Genomics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bionano Genomics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-18-23-18-29-41-72-132-232
111113913
00000-5,0001,0000
-20-2-4-3-7-282
-21056204790
0001,0001,0001,00001,000
00000000
-23-20-19-29-38-71-124-125
-1-10000-2-1
-1-100-2-2788224
0000-2-2778525
00000000
10169-4-15070
23171920683522357
251735306133623113
-----2.00-1.00--14.00
00000000
0-415021-13-1912
-24.85-21.84-20.27-29.59-38.31-72.75-127.23-126.87
00000000

Bionano Genomics stock margins

The Bionano Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bionano Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bionano Genomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bionano Genomics's sales revenue. A higher gross margin percentage indicates that the Bionano Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bionano Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bionano Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bionano Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bionano Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bionano Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bionano Genomics Margin History

Bionano Genomics Gross marginBionano Genomics Profit marginBionano Genomics EBIT marginBionano Genomics Profit margin
2029e26.49 %0 %27.74 %
2028e26.49 %-2.88 %11.78 %
2027e26.49 %-28.28 %-11 %
2026e26.49 %-52.05 %-48.66 %
2025e26.49 %-92.75 %-98.83 %
2024e26.49 %-205.48 %-283.61 %
202326.49 %-382.01 %-643.74 %
202221.4 %-467.27 %-476.98 %
202121.52 %-420.47 %-402.89 %
202032.59 %-435.88 %-483.65 %
201933.17 %-255.48 %-294.37 %
201827.42 %-170.17 %-154.17 %
201736.49 %-237.85 %-245.74 %
201647.28 %-311.78 %-277.61 %

Bionano Genomics Stock Sales Revenue, EBIT, Earnings per Share

The Bionano Genomics earnings per share therefore indicates how much revenue Bionano Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bionano Genomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bionano Genomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bionano Genomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bionano Genomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bionano Genomics Revenue, EBIT and net profit per share

DateBionano Genomics Sales per ShareBionano Genomics EBIT per shareBionano Genomics Earnings per Share
2029e2.24 undefined0 undefined0.62 undefined
2028e1.65 undefined0 undefined0.19 undefined
2027e1.21 undefined0 undefined-0.13 undefined
2026e0.64 undefined0 undefined-0.31 undefined
2025e0.51 undefined0 undefined-0.5 undefined
2024e0.42 undefined0 undefined-1.19 undefined
20231.06 undefined-4.04 undefined-6.81 undefined
20220.96 undefined-4.49 undefined-4.59 undefined
20210.65 undefined-2.73 undefined-2.62 undefined
20200.81 undefined-3.55 undefined-3.94 undefined
20196.75 undefined-17.25 undefined-19.88 undefined
201811.88 undefined-20.22 undefined-18.32 undefined
201710.01 undefined-23.81 undefined-24.6 undefined
20167.15 undefined-22.28 undefined-19.84 undefined

Bionano Genomics business model

Bionano Genomics Inc. is a biotechnology company specializing in the development of DNA analysis systems. The company is headquartered in California and was founded in 2003. History: The company was originally established as a research group at the University of California, San Diego. Over the years, the group has evolved into a leading company in DNA analysis and genome analysis. Business model: Bionano Genomics Inc. has a business model based on the analysis and processing of DNA sequences. The company offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Products: The company has introduced a range of products that help revolutionize genomics. One of Bionano Genomics' most important products is the Saphyr system. This system uses optical DNA mapping technology to make DNA sorting and mapping more efficient. The Saphyr system can contribute to improving and accelerating genomic research in various industries. Another product of the company is the COVID-19 assay. This assay is used in the detection of COVID-19. It is used in the laboratory and is fast and accurate. Divisions: Bionano Genomics offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Genomic research: Bionano Genomics works closely with research institutes and companies to perform DNA analysis. The Saphyr system is used to analyze DNA samples and conduct genome studies. With this technology, it has become possible to visualize large genomic regions to gain insights into complex genomic changes and rearrangements, such as those related to cancer. Clinical research: The company works closely with clinicians to conduct clinical studies and diagnose diseases. The Saphyr system can help in the investigation of structural DNA variants associated with specific diseases such as autism, schizophrenia, and epilepsy. Diagnostics: Bionano Genomics also offers services for the diagnosis of genetic disorders. The company provides tests that examine genetic markers and indicators to make an accurate diagnosis. The company also offers genetic counseling services to help families affected by genetic diseases. Overall, Bionano Genomics has the potential to change the way we study, diagnose, and treat genetic diseases. The company has already formed partnerships with several industry leaders and research institutions to advance its research. Bionano Genomics is one of the most popular companies on Eulerpool.com.

Bionano Genomics SWOT Analysis

Strengths

Bionano Genomics Inc possesses several strengths that contribute to its competitiveness and potential for growth. These strengths include:

  • Advanced Genomic Mapping Technology: Bionano Genomics has developed a cutting-edge genomic mapping platform that enables high-resolution analysis of DNA structural variations. This technology provides a significant advantage over traditional methods, offering improved accuracy and faster results.
  • Strong Intellectual Property Portfolio: The company holds a robust intellectual property portfolio with numerous patents, protecting its innovative technologies and providing a competitive edge in the genomics industry.
  • Innovative Research and Development: Bionano Genomics invests heavily in research and development, continuously striving for technological advancements and fostering innovation. This commitment allows them to develop new products and stay ahead of market trends.
  • Strategic Partnerships: The company has established strategic partnerships with key players in the genomics industry, including research institutions and healthcare organizations. These collaborations enhance Bionano Genomics' access to resources, expertise, and potential customer bases.

Weaknesses

Despite its strengths, Bionano Genomics Inc faces certain weaknesses that could hinder its growth and competitive position:

  • Market Penetration Challenges: The genomics industry is highly competitive, and penetrating the market can be challenging for a relatively smaller company like Bionano Genomics. Established competitors with greater brand recognition and market share may pose obstacles to widespread adoption of their technology.
  • Dependency on Research Grants: Bionano Genomics relies on research grants to fund a significant portion of its operations. The uncertainty and variability of grant funding may make it difficult to sustain consistent growth and investments in innovation.
  • Limited Product Portfolio: Currently, Bionano Genomics primarily focuses on genomic mapping technology. Diversification of their product portfolio may be necessary to mitigate potential risks associated with reliance on a single technology and to target a broader customer base.

Opportunities

Bionano Genomics Inc has several opportunities that can be leveraged to drive growth and success in the genomics industry:

  • Rising Demand for Genomic Analysis: The increasing interest in personalized medicine and genetic research presents a significant opportunity for Bionano Genomics. Their advanced genomic mapping technology can support various applications, such as identifying disease-causing genetic variations and guiding targeted therapies.
  • Expansion into New Markets: Bionano Genomics can explore new market segments, such as agricultural genomics or forensic genetics, to diversify its customer base and revenue streams. These markets offer untapped potential for the application of genomic analysis technologies.
  • International Expansion: The company can target international markets to expand its global presence. Collaborations with international institutions and partnerships with local companies can help establish a strong foothold in diverse regions with emerging genomics markets.

Threats

Bionano Genomics Inc faces certain threats that may impact its growth and competitiveness:

  • Intense Competition: The genomics industry is characterized by intense competition, with established players and new entrants vying for market share. Bionano Genomics must continuously innovate and differentiate itself to keep up with competitors and maintain a competitive edge.
  • Regulatory Challenges: The regulatory environment governing genetic testing and genomic analysis is complex and subject to change. Compliance with evolving regulations poses challenges for Bionano Genomics, as non-compliance can lead to legal and reputational consequences.
  • Technological Advancements: Rapid advancements in genomics technologies pose the risk of making Bionano Genomics' current offerings obsolete or less competitive. The company must stay at the forefront of technological developments and continuously improve its products to stay relevant in the marketplace.
  • Global Economic Conditions: Economic downturns or fluctuations can impact investments in healthcare and research, potentially affecting Bionano Genomics' ability to secure funding, make sales, and sustain growth. Geopolitical factors and trade regulations can also influence the company's international expansion plans.

Bionano Genomics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bionano Genomics Revenue by Segment

Segmente202320222021202020192018
Product revenue26.73 M USD20.43 M USD-6.23 M USD9.47 M USD11.46 M USD
Service and other revenue9.39 M USD7.38 M USD-2.27 M USD655,064 USD-
Instruments--5.89 M USD---
Consumables--5.81 M USD---
Other revenue-----537,562 USD

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Bionano Genomics Revenue by Segment

Segmente202320222021202020192018
Product revenue--11.7 M USD---
Service and other revenue--6.29 M USD---

Bionano Genomics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Bionano Genomics Revenue by Segment

DateAmericasAsia PacificEMEAEMEIANorth America
202318.02 M USD5.13 M USD12.96 M USD--
202213.86 M USD4.98 M USD8.96 M USD--
2021-3.05 M USD-5.6 M USD9.33 M USD
2020-850,931 USD-3.16 M USD4.49 M USD
2019-1.47 M USD-3.63 M USD5.03 M USD
2018-3.45 M USD-3.95 M USD4.59 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bionano Genomics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bionano Genomics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bionano Genomics shares outstanding

The number of shares was Bionano Genomics in 2023 — This indicates how many shares 34.15 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bionano Genomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bionano Genomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bionano Genomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bionano Genomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bionano Genomics stock splits

In Bionano Genomics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Bionano Genomics.

Bionano Genomics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.43 -0.22  (48.24 %)2024 Q2
3/31/2024-0.66 -0.51  (22.48 %)2024 Q1
12/31/2023-0.89 -0.41  (53.93 %)2023 Q4
9/30/2023-0.99 -1  (-1.07 %)2023 Q3
6/30/2023-1.05 -1.24  (-17.65 %)2023 Q2
3/31/2023-1.12 -1.2  (-6.95 %)2023 Q1
12/31/2022-1.12 -1.3  (-15.86 %)2022 Q4
9/30/2022-1.17 -1.1  (6.22 %)2022 Q3
6/30/2022-0.93 -1.1  (-18.08 %)2022 Q2
3/31/2022-0.77 -1.1  (-43.79 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Bionano Genomics stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

39

👫 Social

20

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bionano Genomics shareholders

%
Name
Stocks
Change
Date
5.81395 % Armistice Capital LLC5,000,0003,322,0008/12/2024
2.43023 % The Vanguard Group, Inc.2,089,997195,2366/30/2024
0.70633 % BlackRock Institutional Trust Company, N.A.607,444222,3296/30/2024
0.69676 % Geode Capital Management, L.L.C.599,215197,8356/30/2024
0.61658 % GMT Capital Corp.530,260530,2606/30/2024
0.18212 % Cetera Investment Advisers LLC156,6258,9746/30/2024
0.17070 % Cetera Advisors LLC146,806146,8063/31/2024
0.15273 % Northern Trust Investments, Inc.131,34639,9796/30/2024
0.13254 % State Street Global Advisors (US)113,98806/30/2024
0.09890 % Carret Asset Management, LLC85,05540,0559/30/2024
1
2
3
4
5
...
10

Bionano Genomics Executives and Management Board

Dr. R. Erik Holmlin(55)
Bionano Genomics President, Chief Executive Officer, Director (since 2011)
Compensation 2.77 M
Mr. Mark Oldakowski(49)
Bionano Genomics Chief Operating Officer
Compensation 1.5 M
Dr. Alka Chaubey(50)
Bionano Genomics Chief Medical Officer
Compensation 1.32 M
Dr. Aleksandar Rajkovic(59)
Bionano Genomics Independent Director
Compensation 451,179
Mr. Christopher Stewart(54)
Bionano Genomics Chief Financial Officer
Compensation 252,378
1
2
3

Bionano Genomics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
OPKO Health Stock
OPKO Health
SupplierCustomer0,660,430,880,800,410,32
Quest Diagnostics Stock
Quest Diagnostics
SupplierCustomer0,510,270,310,820,100,12
PerkinElmer Stock
PerkinElmer
SupplierCustomer0,510,780,810,800,060,16
AS ONE Stock
AS ONE
SupplierCustomer0,490,690,860,520,430,39
AddLife B Stock
AddLife B
SupplierCustomer0,230,570,720,810,470,24
Corteva Stock
Corteva
SupplierCustomer0,220,600,25-0,56-0,790,29
Medicover B Stock
Medicover B
SupplierCustomer-0,050,280,690,760,280,36
Berry Genomics A Stock
Berry Genomics A
SupplierCustomer-0,30-0,720,620,800,90-0,31
1

Most common questions regarding Bionano Genomics

What values and corporate philosophy does Bionano Genomics represent?

Bionano Genomics Inc represents a strong commitment to advancing genomics research and revolutionizing the field of DNA analysis. The company's corporate philosophy revolves around developing innovative and high-quality genomic technology solutions that enable scientists and researchers to gain a better understanding of the human genome and its impact on human health. By leveraging their proprietary Saphyr system, Bionano Genomics Inc aims to provide accurate and comprehensive structural variation detection, offering valuable insights into genetic diseases and ultimately contributing to precision medicine. With a focus on collaboration, integrity, and continuous innovation, Bionano Genomics Inc strives to empower the scientific community in unraveling the complexities of the genome.

In which countries and regions is Bionano Genomics primarily present?

Bionano Genomics Inc is primarily present in the United States.

What significant milestones has the company Bionano Genomics achieved?

Bionano Genomics Inc has achieved significant milestones in its journey. One of the major accomplishments is the development of the Saphyr System, a revolutionary genomic platform that enables the detection of structural variations in DNA. This cutting-edge technology has paved the way for advancements in genomics research, allowing scientists and clinicians to gain a deeper understanding of genetic diseases and cancer. Furthermore, Bionano Genomics has successfully established collaborations with renowned research institutions and biotech companies, further validating its innovative solutions. With its continuous dedication to advancing genomics, Bionano Genomics Inc stands as a frontrunner in the field, driving breakthroughs in personalized medicine and genetic diagnostics.

What is the history and background of the company Bionano Genomics?

Bionano Genomics Inc is a leading genomics company that specializes in revolutionary tools for structural variation analysis and genome mapping. Founded in 2003, the company has emerged as a key player in the genomics industry, catering to the needs of researchers and clinicians worldwide. Bionano Genomics Inc has developed the Saphyr system, a cutting-edge platform that offers high-resolution detection of structural variations in the human genome. Leveraging its expertise in optical genome mapping, Bionano Genomics Inc has made significant contributions to the study of genetic diseases, cancer research, and agrigenomics. With its innovative technologies, Bionano Genomics Inc is committed to advancing genomics research and revolutionizing the way genetic variations are detected and understood.

Who are the main competitors of Bionano Genomics in the market?

The main competitors of Bionano Genomics Inc in the market include companies such as Illumina Inc, Pacific Biosciences of California Inc, and Oxford Nanopore Technologies.

In which industries is Bionano Genomics primarily active?

Bionano Genomics Inc is primarily active in the field of life sciences and biotechnology.

What is the business model of Bionano Genomics?

Bionano Genomics Inc operates under the business model of developing and commercializing innovative technologies for genome analysis. The company specializes in optical mapping, an approach that provides high-resolution analysis of genomic structural variation. Bionano Genomics Inc's platform, Saphyr system, enables researchers to detect and study variations in DNA in a more accurate and efficient manner. By offering a unique solution for genome analysis, Bionano Genomics Inc aims to improve disease research, diagnostic testing, and drug development processes.

What is the P/E ratio of Bionano Genomics 2024?

The Bionano Genomics P/E ratio is -0.08.

What is the P/S ratio of Bionano Genomics 2024?

The Bionano Genomics P/S ratio is 0.23.

What is the Quality Investing of Bionano Genomics?

The Quality Investing for Bionano Genomics is 3/10.

What is the revenue of Bionano Genomics 2024?

The expected Bionano Genomics revenue is 36.09 M USD.

How high is the profit of Bionano Genomics 2024?

The expected Bionano Genomics profit is -102.34 M USD.

What is the business model of Bionano Genomics

Bionano Genomics Inc. is a company specialized in the development of devices for genomic research. The company offers both hardware and software solutions that allow researchers to collect fast and precise data on DNA sequencing. The business model of Bionano is based on three main sectors: genomic research in the areas of health, agriculture, and industrial biotechnology. The company provides a variety of solutions in each of these sectors to ensure that customers can achieve their specific research goals. Bionano offers innovative technology for genome analysis and sequencing, supports research in health, agriculture, and industrial biotechnology, and provides products like the Saphyr® system to assist researchers in working quickly and efficiently.

What is the Bionano Genomics dividend?

Bionano Genomics pays a dividend of 0 USD distributed over payouts per year.

How often does Bionano Genomics pay dividends?

The dividend cannot currently be calculated for Bionano Genomics or the company does not pay out a dividend.

What is the Bionano Genomics ISIN?

The ISIN of Bionano Genomics is US09075F1075.

What is the Bionano Genomics WKN?

The WKN of Bionano Genomics is A2JRLZ.

What is the Bionano Genomics ticker?

The ticker of Bionano Genomics is BNGO.

How much dividend does Bionano Genomics pay?

Over the past 12 months, Bionano Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionano Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bionano Genomics?

The current dividend yield of Bionano Genomics is .

When does Bionano Genomics pay dividends?

Bionano Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bionano Genomics?

Bionano Genomics paid dividends every year for the past 0 years.

What is the dividend of Bionano Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bionano Genomics located?

Bionano Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bionano Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bionano Genomics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Bionano Genomics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Bionano Genomics in the year 2023?

In the year 2023, Bionano Genomics distributed 0 USD as dividends.

In which currency does Bionano Genomics pay out the dividend?

The dividends of Bionano Genomics are distributed in USD.

All fundamentals about Bionano Genomics

Our stock analysis for Bionano Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionano Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.